Exposure-oriented molecular profiling and machine learning prioritize the citrus flavonoid nobiletin as an antitumor candidate for colorectal cancer: integrated pharmacological evaluation
Colorectal cancer (CRC) remains a major health burden, and the pharmacologically relevant constituents of complex natural-product preparations are difficult to prioritize because chemical presence does not necessarily reflect systemic exposure. Here, we established an exposure-oriented pharmacological workflow integrating ultra-performance liquid chromatography–quadrupole time-of-flight tandem mass spectrometry (UPLC-QTOF-MS/MS) serum profiling, machine learning, public human CRC single-cell RNA sequencing, target integration, molecular modeling, and experimental evaluation to identify and characterize a prioritized bioactive candidate from Wumen Xianzhu Jiedu Decoction (WMXZJDD). Serum profiling after oral administration annotated 127 serum-exposure-related features, including 42 prototype components and 85 putative metabolites. After parent-compound mapping, deduplication, and structural filtering, 47 exposure-related parent compounds were retained for machine-learning prioritization. Nobiletin (NOB), a citrus-derived polymethoxylated flavonoid, ranked first according to the four-model composite prioritization score (0.77). Integrative analyses supported MAPK/JNK signaling as a candidate mechanism underlying NOB activity. NOB inhibited CT26 cell proliferation (24-h IC 50 , 70.8 μM) and reduced EdU incorporation, accompanied by increased JNK phosphorylation and upregulation of Beclin-1, ATG5, and NCOA4. In syngeneic CT26 tumor-bearing mice, NOB suppressed tumor growth without treatment-associated body-weight loss. These findings prioritize NOB as an anti-CRC candidate within an exposure-informed screening framework and illustrate the potential of integrating serum profiling, machine learning, and pharmacological evaluation for active-component discovery from complex natural-product preparations.
Authors
- Yingqi Yang
- Zhiyang Chen (ORCID: https://orcid.org/0000-0002-9341-7483)
- Jiacheng Li (ORCID: https://orcid.org/0009-0007-1308-2550)
- Wang Xiaopeng
- Meiyao Chen
- Ziwei Xiong
- Sicheng Shen
- Zhuoqun Zhu
- Jiajia Wan
- Chuyue Wang
Institutions
- Nanjing University of Chinese Medicine (CN)
- Suzhou Traditional Chinese Medicine Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3389/fphar.2026.1976105
- Primary Topic
- Bioactive Compounds in Plants
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nanjing University of Chinese Medicine